[go: up one dir, main page]

PE20141200A1 - Formulacion de una capsula que comprende montelukast y levocetirizina - Google Patents

Formulacion de una capsula que comprende montelukast y levocetirizina

Info

Publication number
PE20141200A1
PE20141200A1 PE2014000056A PE2014000056A PE20141200A1 PE 20141200 A1 PE20141200 A1 PE 20141200A1 PE 2014000056 A PE2014000056 A PE 2014000056A PE 2014000056 A PE2014000056 A PE 2014000056A PE 20141200 A1 PE20141200 A1 PE 20141200A1
Authority
PE
Peru
Prior art keywords
formulation
levocetirizine
capsule
capsule including
layer
Prior art date
Application number
PE2014000056A
Other languages
English (en)
Inventor
Yong Il Kim
Dong Ho Kim
Taek Kwan Kwon
Kyeong Soo Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47839311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141200(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PE20141200A1 publication Critical patent/PE20141200A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA FORMULACION DE UNA CAPSULA QUE COMPRENDE DOS CAPAS SEPARADAS DE : a) UNA CAPA DE MONTELUKAST, b) UNA CAPA DE LEVOCETIRIZINA, c) UN ADITIVO QUE SE SELCCIONA DEL GRUPO DE UN DESINTEGRANTE, UN AGLUTINANTE, UN AGENTE ESTABILIZANTE ENTRE OTROS. DICHA FORMULACION DE LA CAPSULA PRESENTA UNA CAPA DE RECUBRIMIENTO QUE COMPRENDE UN SUSTRATO SELECCIONADO DEL GRUPO DE METILCELULOSA, ETILCELULOSA, HIPROMELOSA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DE DICHA FORMULA QUE ES UTIL PARA EL TRATAMIENTO DE LA RINITIS ALERGICA.
PE2014000056A 2011-07-15 2012-07-11 Formulacion de una capsula que comprende montelukast y levocetirizina PE20141200A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110070680 2011-07-15
KR1020110111132A KR20130009553A (ko) 2011-07-15 2011-10-28 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제

Publications (1)

Publication Number Publication Date
PE20141200A1 true PE20141200A1 (es) 2014-09-29

Family

ID=47839311

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000056A PE20141200A1 (es) 2011-07-15 2012-07-11 Formulacion de una capsula que comprende montelukast y levocetirizina

Country Status (22)

Country Link
US (2) US20140170213A1 (es)
EP (1) EP2731594B1 (es)
JP (1) JP2014520842A (es)
KR (2) KR20130009553A (es)
CN (2) CN103687591A (es)
AR (1) AR087177A1 (es)
BR (1) BR112014000943A2 (es)
CL (1) CL2014000054A1 (es)
CO (1) CO6880062A2 (es)
ES (1) ES2727861T3 (es)
HK (1) HK1246199A1 (es)
JO (1) JO3551B1 (es)
MX (1) MX366509B (es)
MY (1) MY178890A (es)
PE (1) PE20141200A1 (es)
PH (1) PH12014500066A1 (es)
RU (1) RU2606857C2 (es)
SA (1) SA112330689B1 (es)
TW (1) TW201311241A (es)
UA (1) UA112083C2 (es)
WO (1) WO2013012199A1 (es)
ZA (1) ZA201401143B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012014521A (es) 2010-06-16 2013-05-20 Bruce Chandler May Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
KR101418404B1 (ko) * 2012-01-06 2014-07-10 한미약품 주식회사 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
RU2677649C2 (ru) * 2013-02-21 2019-01-18 Глэнмарк Фармасьютикалс Лимитед Фармацевтические композиции монтелукаста и левоцетиризина
ES2770760T3 (es) * 2013-03-13 2020-07-03 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesiones traumáticas
AU2014249534B2 (en) 2013-03-13 2018-08-30 IRR, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
KR20150138848A (ko) * 2013-03-13 2015-12-10 인플래머토리 리스폰스 리서치, 아이엔씨. 레보세티리진 및 몬테루카스트의 과민증 치료 용도
KR20150138849A (ko) 2013-03-13 2015-12-10 인플래머토리 리스폰스 리서치, 아이엔씨. 레보세티리진 및 몬테루카스트의 자가면역질환의 치료 용도
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
WO2015069203A1 (en) * 2013-11-06 2015-05-14 Santa Farma Ilaç Sanayi A.Ş. Capsule comprising rupatadine fumarate and montelukast sodium
KR101669556B1 (ko) * 2014-07-02 2016-10-28 한미약품 주식회사 몬테루카스트 또는 이의 약제학적으로 허용가능한 염의 경구투여용 액상제제
JP6575031B2 (ja) * 2014-07-28 2019-09-18 日本ケミファ株式会社 モンテルカストナトリウム製剤
EP3193875B1 (en) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
PL3222279T3 (pl) 2016-03-21 2022-05-09 Invest Bielany Spółka Z Ograniczoną Odpowiedzialnością Doustny preparat farmaceutyczny montelukastu i lewocetyryzyny oraz sposób jego wytwarzania
AU2018253392B2 (en) 2017-04-14 2023-11-02 Capsugel Belgium Nv Process for making pullulan
AU2018251256B2 (en) 2017-04-14 2023-10-05 Capsugel Belgium Nv Pullulan capsules
EP4153178A4 (en) 2020-05-19 2024-06-05 Irr, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
KR20210152280A (ko) 2020-06-08 2021-12-15 주식회사 경보제약 몬테루카스트와 레보세티리진을 포함하는 안정성이 향상된 단일 정제 및 이의 제조방법
KR102481517B1 (ko) 2021-08-30 2022-12-27 주식회사 클라시아 약제학적 제제
EP4321156A4 (en) 2021-10-21 2025-05-07 Han Wha Pharma Co., Ltd. FILM-COATED TABLET WITH IMPROVED STABILITY CONTAINING MONTELUKAST OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND LEVOCETIRIZINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT
KR20240045586A (ko) 2022-09-30 2024-04-08 주식회사 제뉴원사이언스 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 포함하는 안정성이 향상된 이층정 정제 및 그의 제조방법
KR20250005771A (ko) 2023-07-03 2025-01-10 경동제약 주식회사 레보세티리진 및 몬테루카스트를 포함하는 복합 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2588188B1 (fr) * 1985-10-04 1988-01-08 Delalande Sa Comprime de sel(s) hydrosoluble(s) de cinepazide a liberation programmee et son procede de preparation
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
WO1994006429A1 (en) 1992-09-24 1994-03-31 Sepracor, Inc. Compositions for treating allergic disorders using (-) cetirizine
RU2108787C1 (ru) * 1993-09-01 1998-04-20 Роммерс С.А.И.С.Ф. Фармацевтические мягкие капсулы, содержащие лизинхлониксинат, способ их получения
WO1999032125A1 (en) * 1997-12-23 1999-07-01 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
RU2286784C2 (ru) 2001-06-28 2006-11-10 ЮСиБи ФАРШИМ С.А. Таблетка, содержащая цетиризин и псевдоэфедрин
KR20090029314A (ko) * 2001-06-28 2009-03-20 유씨비 파쉼 소시에떼아노님 세티리진 및 슈도에페드린을 포함하는 정제
WO2005089171A2 (en) * 2004-03-11 2005-09-29 Mullally John P Protocol for improving vision
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
CN101073563B (zh) * 2007-02-07 2010-10-06 西安利君制药有限责任公司 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片
EP2180891A4 (en) * 2007-08-13 2010-12-29 Hanall Biopharma Co Ltd COMBINATION PREPARATION WITH HMG COA REDUCTASE INHIBITORS AND ASPIRIN AND METHOD FOR THE PRODUCTION THEREOF
RU2405542C2 (ru) * 2008-11-19 2010-12-10 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Мягкая экструзионная капсула, способ приготовления раствора для ее наполнения, способ получения капсул и способ увеличения плотности агаровой оболочки
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations

Also Published As

Publication number Publication date
CN103687591A (zh) 2014-03-26
MY178890A (en) 2020-10-21
EP2731594B1 (en) 2019-04-24
EP2731594A1 (en) 2014-05-21
BR112014000943A2 (pt) 2017-02-14
WO2013012199A1 (en) 2013-01-24
UA112083C2 (uk) 2016-07-25
CO6880062A2 (es) 2014-02-28
ZA201401143B (en) 2015-04-29
JO3551B1 (ar) 2020-07-05
SA112330689B1 (ar) 2017-03-02
RU2606857C2 (ru) 2017-01-10
EP2731594A4 (en) 2014-12-31
CN107468667A (zh) 2017-12-15
US20140170213A1 (en) 2014-06-19
AR087177A1 (es) 2014-02-26
RU2014105577A (ru) 2015-08-27
ES2727861T3 (es) 2019-10-21
MX2014000312A (es) 2014-02-19
JP2014520842A (ja) 2014-08-25
KR102006000B1 (ko) 2019-08-01
US20160089339A1 (en) 2016-03-31
TW201311241A (zh) 2013-03-16
CL2014000054A1 (es) 2014-07-11
KR20130009553A (ko) 2013-01-23
PH12014500066A1 (en) 2014-03-24
WO2013012199A8 (en) 2014-02-06
MX366509B (es) 2019-07-11
KR20180090966A (ko) 2018-08-14
HK1246199A1 (zh) 2018-09-07

Similar Documents

Publication Publication Date Title
PE20141200A1 (es) Formulacion de una capsula que comprende montelukast y levocetirizina
IL264413B (en) Preparations containing fibers obtained electrohydrodynamically for delivering specific doses of active substance to the skin or mucous membrane
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
JOP20140104B1 (ar) مركبات ثنائى اريل اميد كمثبطات كيناز
CO2017006214A2 (es) Derivados de quinazolina utilizados para tratar el vih
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
EA201690962A1 (ru) Составы
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CU24244B1 (es) Composición farmacéutica recubierta que contiene regorafenib
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
CL2014002077A1 (es) Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple.
BR112017004741A2 (pt) compostos e composições como inibidores da raf quinase
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
DOP2016000253A (es) Nuevos compuestos
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
EA201591830A1 (ru) Фармацевтические композиции, включающие эверолимус
DOP2016000120A (es) Nuevos inhibidores de dgat2
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
BR112017006690A8 (pt) Composto derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo

Legal Events

Date Code Title Description
FC Refusal